Stocks and InvestingStocks and Investing
Mon, April 3, 2023
Sat, April 1, 2023
Fri, March 31, 2023
Thu, March 30, 2023

Kristen Kluska Maintained (TSHA) at Buy with Decreased Target to $2 on, Mar 30th, 2023


Published on 2024-10-28 02:30:46 - WOPRAI, Kristen Kluska
  Print publication without navigation


Kristen Kluska of Cantor Fitzgerald, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Buy with Decreased Target from $13 to $2 on, Mar 30th, 2023.

Kristen has made no other calls on TSHA in the last 4 months.



There are 8 other peers that have a rating on TSHA. Out of the 8 peers that are also analyzing TSHA, 3 agree with Kristen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yun Zhong of "BTIG" Downgraded from Strong Buy to Hold on, Thursday, February 2nd, 2023
  • Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $1.5 on, Wednesday, February 1st, 2023
  • Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $3 on, Friday, January 27th, 2023


These are the ratings of the 5 analyists that currently disagree with Kristen


  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $6 on, Wednesday, March 29th, 2023
  • Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $3 on, Wednesday, March 29th, 2023
  • Whitney Ijem of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $13 on, Wednesday, February 1st, 2023
  • Jack Allen of "Baird" Maintained at Buy with Decreased Target to $6 on, Wednesday, February 1st, 2023
  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023